Please assess the completion status of the following clinical trial:

Trial Title: Physical and Chemical Study of Atherosclerosis Mechanisms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent form~* dyslipidemia (HDL \<1.0 mmol / l, triglycerides (TG) in plasma ≥ 1,7 mmol / l or cholesterol ≥ 5,6 mmol /l)~* waist circumference ≥ 94.0 cm in men or ≥ 80,0 cm in women,~* BP ≥140/95 mm Hg or a patient is taking antihypertensive medications,~* fasting glucose ≥ 6,1 mmol / l or the patient is taking hypoglycemic agents,~* the possibility of treatment for 6 months and follow-up for 1 year~Exclusion Criteria:~* Absence of consent form~* Non-compliance of patient to necessary recommendations.~* The presence of mental illness.~* Complete immobilization of a patient (paresis, and paralysis).

- Gender: ALL
- Minimum Age: 26 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Conventional treatment (Type: ACTIVE_COMPARATOR): Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day.
- Weight loss treatment (Type: EXPERIMENTAL): Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).